Citigroup
NXTC icon

Citigroup’s NextCure NXTC Stock Holding History

Citigroup’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$11 – 6095
2026
Q1 		$11 Buy
+1
New +$12 ﹤0.01% 5733
2025
Q4 		– Sell
-1
Closed -$6 – 6339
2025
Q3 		$6 Sell
1
-85,455
-100% -$447K ﹤0.01% 5974
2025
Q2 		$472K Sell
85,456
-32,825
-28% -$176K ﹤0.01% 3662
2025
Q1 		$682K Buy
118,281
+2,528
+2% +$22.3K ﹤0.01% 3511
2024
Q4 		$1.07M Buy
+115,753
New +$1.7M ﹤0.01% 3307
2022
Q4 		– Sell
-27
Closed -$1K – 5902
2022
Q3 		$1K Sell
27
-8
-23% -$408 ﹤0.01% 5658
2022
Q2 		$2K Sell
35
-15
-30% -$783 ﹤0.01% 5905
2022
Q1 		$3K Sell
50
-20
-29% -$1.25K ﹤0.01% 5970
2021
Q4 		$5K Sell
70
-52
-43% -$4.35K ﹤0.01% 5662
2021
Q3 		$10K Sell
122
-27
-18% -$2.37K ﹤0.01% 5469
2021
Q2 		$14K Sell
149
-266
-64% -$27.2K ﹤0.01% 5506
2021
Q1 		$50K Sell
415
-294
-41% -$42.6K ﹤0.01% 4711
2020
Q4 		$93K Buy
709
+603
+569% +$77.9K ﹤0.01% 5592
2020
Q3 		$12K Sell
106
-396
-79% -$48.7K ﹤0.01% 6506
2020
Q2 		$130K Sell
502
-202
-29% -$76.9K ﹤0.01% 5354
2020
Q1 		$314K Sell
704
-62
-8% -$33.1K ﹤0.01% 4314
2019
Q4 		$518K Buy
766
+754
+6,283% +$378K ﹤0.01% 4391
2019
Q3 		$4K Sell
12
-55
-82% -$17.9K ﹤0.01% 7396
2019
Q2 		$12K Buy
+67
New +$13.9K ﹤0.01% 7256

Other funds holding NXTC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Citigroup's NXTC Position: Q2 2026 in Review

Citigroup sold out of NextCure (NXTC) in Q2 2026, closing a stake of 1 share — an estimated $11 sold.

Citigroup first reported a position in NXTC in Q2 2019 and held it in 19 quarters. The position peaked at $1.07M in Q4 2024. 17 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • Citigroup reported no remaining NextCure position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 1 NextCure share in Q2 2026, an estimated $11.
  • Citigroup first reported a position in NextCure in Q2 2019 and held it in 19 quarters.
  • Citigroup's NextCure position peaked at $1.07M in Q4 2024.
  • 17 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.